CJC-1295 (no DAC) | Ipamorelin 5/5 mg

Description

⚠ For laboratory research use only. Not for human consumption.

This product is a blend of CJC-1295 (no DAC) and Ipamorelin.

Appearance: white powder

Form: Lyophilized powder
Storage: 2-8°
Purity: ≥99

 

CJC-1295 (no DAC)
CAS NO: 863288-34-0
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.9 g/mol

 

IPAMORELIN
CAS NO: 170851-70-4
Molecular Formula: C38H49N10O
Molecular Weight: 711.9 g/mol

CJC-1295 No DAC 5mg (Modified GRF 1-29) – A Growth Hormone-Releasing Peptide for Endocrine and Metabolic Research, Intended for laboratory use only by qualified researchers. This product is strictly not for human or veterinary consumption.

---

Primary Research Applications:

• Pituitary Somatotroph Function & GH Secretion Studies
• GHRH Receptor Signaling & cAMP Pathway Analysis
• Comparative Research with DAC-Containing Analogs
• Pulsatile GH Release & Metabolic Modeling

---

A PRECISE TOOL FOR PULSATILE GH RESEARCH: A GUIDE TO CJC-1295 NO DAC

Welcome, esteemed researchers, to Elite Wellness Peptide’s detailed examination of a refined growth hormone-releasing peptide: CJC-1295 No DAC (also known as Modified GRF 1-29 or Tetrasubstituted GRF). This product contains 5mg of high-purity, lyophilized peptide, representing a precise tool for investigating the dynamics of the hypothalamic-pituitary axis. CJC-1295 No DAC is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), modified for enhanced stability and receptor binding, while specifically lacking the Drug Affinity Complex (DAC) moiety that confers extended duration of action. This deliberate design allows researchers to study pulsatile growth hormone (GH) release patterns without the sustained elevation associated with the DAC version. This product description serves as a foundational research primer to guide your experimental design in endocrinology, metabolism, and cellular signaling.

---

SECTION 1: THE SCIENTIFIC BASIS OF CJC-1295 NO DAC’S MECHANISM OF ACTION

The research value of CJC-1295 No DAC lies in its targeted interaction with the growth hormone-releasing hormone receptor (GHRH-R) and its ability to stimulate natural, pulsatile GH secretion patterns.

1. Targeted GHRH Receptor Agonism:CJC-1295 No DAC is a potent, synthetic agonist of the GHRH receptor, which is primarily expressed on somatotroph cells in the anterior pituitary gland. Upon binding to this G-protein-coupled receptor, it initiates a signaling cascade involving cyclic AMP (cAMP) and protein kinase A (PKA), leading to the synthesis and secretion of growth hormone (GH) from storage vesicles.

 

2. Enhanced Stability Through Structural Modification:The peptide is a tetra-substituted analog of the endogenous GHRH (1-29) sequence. It incorporates modifications (specifically, substituting the first two amino acids with D-Ala and modifying positions 8, 15, and 27) that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This results in a significantly extended half-life in experimental models compared to native GHRH (1-29), allowing for more sustained receptor activation in research settings.

 

3. Absence of DAC for Natural Pulsatility:Unlike its counterpart CJC-1295 with DAC, the “No DAC” version lacks the Drug Affinity Complex. The DAC moiety is designed to covalently bind to serum albumin, creating a depot effect and prolonging the molecule’s circulation time to over a week. By omitting this, CJC-1295 No DAC maintains a shorter, more physiological-like half-life, enabling researchers to study the effects of discrete, pulsatile GH stimulation—a critical feature of normal GH physiology—rather than continuous GH elevation.

---

Ipamorelin 5mg: A Comprehensive Overview

Ipamorelin is a cutting-edge pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Renowned for its ability to stimulate the pituitary gland, Ipamorelin promotes the natural release of growth hormone (GH). This peptide is highly regarded for its potential to support lean muscle growth, aid in weight management, and enhance overall wellness. Unlike other growth hormone-releasing peptides, Ipamorelin has minimal impact on key hormones such as:

 

• Thyroid-stimulating hormone (TSH)
• Luteinizing hormone (LH)
• Prolactin
• Follicle-stimulating hormone (FSH)
• Adrenocorticotropic hormone (ACTH)
• Cortisol

 

As a member of the Growth Hormone-Releasing Peptides (GHRPs) family, Ipamorelin is celebrated for its ability to elevate GH levels, offering a range of potential clinical benefits, including:

 

• Improved body composition through fat reduction and weight management
• Enhanced skin elasticity and function
• Reduced cortisol levels for better stress management
• Increased energy levels and improved sleep quality

---

Potential Benefits of Ipamorelin Under Investigation

 

1. Counteracting Glucocorticoid Side Effects

Long-term glucocorticoid use can lead to adverse effects such as inflammation, reduced lean muscle mass, and increased body fat. Research suggests that Ipamorelin may help mitigate these effects by stimulating the pituitary gland, potentially reversing muscle wasting and improving nitrogen balance in muscles.

 

2. Protection Against Bone Loss
   Prolonged glucocorticoid use is associated with decreased bone density and increased fracture risk. Studies indicate that Ipamorelin may help counteract bone loss by promoting bone formation and enhancing bone mineral density, as demonstrated in preclinical trials.

 

3. Potential Support for Diabetes Management
   Emerging research on diabetic models suggests that Ipamorelin may stimulate insulin release by interacting with calcium channels in pancreatic cells. This finding highlights its potential role in supporting metabolic health and diabetes prevention.

 

4. Diagnostic Applications in Cancer and Heart Failure
   Ipamorelin’s interaction with the ghrelin receptor has sparked interest in its use as a positron emission tomography (PET) probe. Preliminary studies suggest it could enhance diagnostic accuracy for certain cancers and heart failure, offering a promising tool for medical imaging.

 

5. Post-Operative Ileus (POI) Recovery

Post-operative ileus, a temporary gastrointestinal paralysis following surgery, can delay recovery. Ipamorelin has shown potential in reducing recovery time and improving nutrient absorption in individuals affected by POI, making it a valuable area of study for post-surgical care.

---

EXPERIMENTAL PREPARATION

For accurate research application:

1. Reconstitutewith appropriate volume of bacteriostatic water
2. Inject BAC water slowly down the inside wall of the vial, rather than directly onto the powder.
3. Gently swirluntil fully dissolved (do not vortex)
4. Administerimmediately or store at 4°C protected from light
5. Reconstituted: Stable 30 days at 4°C

---

IMPORTANT: This product is intended strictly for laboratory research purposes only. NOT for human or animal consumption. NOT for medical or diagnostic use. These products have not undergone evaluation by the U.S. Food and Drug Administration. By purchasing, you confirm compliance with all applicable regulations.